Magdalena holds an MSc in Pharmaceutical Bioscience and an interdisciplinary PhD merging the fields of psychiatry, immunology and neuropharmacology. Her previous research focused on metabolic and immunologic changes in psychotic disorders. She is now focusing on science writing, allowing her to culture her passion for medical science and human health.
The U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for Yonsa (abiraterone acetate) ultramicrosize tablets for the treatment of castration resistant prostate cancer that ... Read more
Modra Pharmaceuticals has enrolled its first patient in a Phase 2 clinical trial (NCT03136640) of ModraDoc006/r as a treatment for metastatic castration-resistant prostate cancer — an advanced and often ... Read more
A new imaging agent appears capable of distinguishing aggressive from benign prostate cancer, potentially helping doctors select with better precision those patients in need of more extensive treatment, a ... Read more
Stereotactic body radiotherapy (SBRT) has shown good long-term outcomes and low rates of severe toxicity, making it a valid treatment option for men with low- and intermediate-risk prostate cancer, according to ... Read more
Three professional societies — the American Urological Association, the American Society for Radiation Oncology and the Society of Urologic Oncology — have issued a series of evidence-based clinical guidelines on how to manage localized prostate ... Read more